MedTrace Logo

Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

NCT04295577 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 388

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a multi-centre, observational (non-interventional) study, designed to follow patients with advanced ovarian fallopian tube and primary peritoneal cancer, who are receiving Niraparib as maintenance treatment, according to the Niraparib access criteria (via TESARO patient access programme, EMA licence and NHS pending NICE assessment due 2018) including assessment of tolerability to Niraparib therapy.

Conditions

Interventions

OTHER

Niraparib

Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].

Sponsors & Collaborators

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Susana Banerjee, MBBS MA PhD FRCP · Royal Marsden NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2026-04-24
Completion
2026-04-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295577 on ClinicalTrials.gov